Skip to main content

Table 1 Baseline characteristics

From: Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

Baseline features (n = 27) N (%)
Median age, years (range) 69 (47–85)
Male 23 (85)
≥2 prior therapies 20 (74)
Organ dysfunction
 Renal dysfunction 17 (63)
 Hepatic dysfunction 7 (26)
 Cardiac dysfunction 11 (41)
 2 organ dysfunctions 8 (30)
Received nivolumab 16 (59)
Median number of doses (range) 7 (1–52)
Disease state
 Renal cell carcinoma 8 (30 %)
 Melanoma 10 (37 %)
 Non-small cell lung cancer 3 (11 %)
 Small cell lung cancer 2 (7 %)
 Urothelial cell carcinoma 4 (15 %)